Citius Pharmaceuticals, Inc. Operating Income Loss

• Citius Pharmaceuticals, Inc. showed an increase of +8.3% in Operating Income Loss from 2024 to 2025.
• This data is from Citius Pharmaceuticals, Inc.'s annual report (Form 10-K), filed with the SEC on December 23, 2025.
• XBRL data for this metric is available from 2010 to 2025 (17 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Over the full 17 years of available data (2010 to 2025), Citius Pharmaceuticals, Inc.'s Operating Income Loss has declined by 248,452.3%.
• Historical annual values: Fiscal year 2025: -$38.53 million | Fiscal year 2024: -$42.00 million | Fiscal year 2023: -$36.73 million | Fiscal year 2022: -$33.32 million | Fiscal year 2021: -$23.53 million | Fiscal year 2020: -$17.71 million | Fiscal year 2019: -$15.60 million | Fiscal year 2018: -$13.79 million | Fiscal year 2017: -$9.99 million | Fiscal year 2016: -$7.45 million | Fiscal year 2015: -$3.23 million | Fiscal year 2014: -$653.8 thousand | Fiscal year 2013: -$1.18 million | Fiscal year 2013: -$28.1 thousand | Fiscal year 2012: -$19.6 thousand | Fiscal year 2011: -$25.6 thousand | Fiscal year 2010: -$15.5 thousand.
• Data sourced from SEC EDGAR public filings as of June 23, 2026.

Last verified: June 23, 2026